How the “OpenAI of stem cell therapy” attracts partners without marketing
Episode description
Micha Breakstone, CEO of Somite.ai, discusses how a single article in Forbes helped Somite to raise $5 million without having to chase investors, why branding Somite as a TechBio, rather than a Biotech, has helped to reduce the perceived risk for investors, and why early-stage science companies should focus their marketing efforts on specific objectives, like securing funding, attracting talent, or establishing partnerships.
In this episode, you'll learn:
02:13 The vision behind Somite.ai
04:18 Timing and strategy for launching Somite.ai
06:45 TechBio vs. Biotech: Understanding the difference
08:59 Partnership models in AI and Biotech
09:58 Creating a digital twin of a human embryo
12:00 Communication strategies for investors
14:09 Leveraging your scientific founders
16:27 Navigating the biotech landscape
17:58 Marketing strategies in science
20:38 Operational excellence and strategy
23:23 Commercialization models in TechBio
23:46 Marketing advice for science startups
26:03 Book recommendations for science communicators
Notes and references:
- The article from Forbes: This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market
- Book recommendation: The Song of the Cell by Siddhartha Mukherjee
To connect with Micha Breakstone:
- LinkedIn
To connect with Joachim Eeckhout, host of the podcast:
- LinkedIn
- Contact form
>>> Subscribe to The Science Marketer newsletter <<<